Clinical efficacy of non-transplant therapies in patients with hepatocellular carcinoma with Child-Pugh C liver cirrhosis

• Published in: Anticancer research Vol. 34; no. 6; pp. 3039 - 3044
• Main Authors: Nishikawa, Hiroki, Kita, Ryuichi, Kimura, Toru, Ohara, Yoshiaki, Takeda, Haruhiko, Sakamoto, Azusa, Saito, Sumio, Nishijima, Norihiro, Nasu, Akihiro, Komekado, Hideyuki, Osaki, Yukio
• Format: Journal Article
• Language: English
• Published: Greece 01.06.2014
• Subjects: Aged; Carcinoma, Hepatocellular - complications; Carcinoma, Hepatocellular - mortality; Carcinoma, Hepatocellular - surgery; Catheter Ablation; Female; Follow-Up Studies; Humans; Liver Cirrhosis - etiology; Liver Cirrhosis - mortality; Liver Cirrhosis - surgery; Liver Neoplasms - complications; Liver Neoplasms - mortality; Liver Neoplasms - surgery; Liver Transplantation; Male; Neoplasm Staging; Patient Selection; Postoperative Complications; Propensity Score; Survival Rate; Treatment Outcome; overall survival; Hepatocellular carcinoma; best supportive care; Child-Pugh C; non-transpalnt therapies
• ISSN: 1791-7530

To compare clinical outcome in patients with Child-Pugh C hepatocellular carcinoma (HCC) treated with non-transplant therapies and those treated with best supportive care. A total of 182 patients with HCC with Child-Pugh C cirrhosis were analyzed. Patients were classified into two groups: patients treated with non-transplant therapies (n=113, treated group) and untreated patients (n=69, untreated group). Furthermore, for reducing the bias in patient selection, a propensity score matching analysis was performed (55 pairs). The median survival time in the treated group was significantly longer than that in the untreated group (1.16 years vs. 0.21 years, p<0.001). After propensity score matching, the median survival time in the treated group remained significantly longer than that in the untreated group (0.95 years vs. 0.17 years, p=0.01). In patients with HCC with Child-Pugh C cirrhosis, those treated with non-transplant therapies might have longer survival than untreated patients.